Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Immunotherapy at large: the road to personalized cancer vaccines.

Literature DB >> 24013748

Immunotherapy at large: the road to personalized cancer vaccines.

Robert H Vonderheide¹, Katherine L Nathanson.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2013 PMID： 24013748 DOI： 10.1038/nm.3317

Source DB: PubMed Journal: Nat Med ISSN： 1078-8956 Impact factor: 53.440

× No keyword cloud information.

16 in total

Review 1. Therapeutic cancer vaccines: current status and moving forward.

Authors: Jeffrey Schlom
Journal: J Natl Cancer Inst Date: 2012-03-06 Impact factor: 13.506

Review 2. From cancer genomics to cancer immunotherapy: toward second-generation tumor antigens.

Authors: J L Schultze; R H Vonderheide
Journal: Trends Immunol Date: 2001-09 Impact factor: 16.687

Review 3. Cancer immunotherapy comes of age.

Authors: Suzanne L Topalian; George J Weiner; Drew M Pardoll
Journal: J Clin Oncol Date: 2011-10-31 Impact factor: 44.544

4. Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome.

Authors: David P Carbone; I Frank Ciernik; Michael J Kelley; M Charles Smith; Sorena Nadaf; Denise Kavanaugh; V Ellen Maher; Michael Stipanov; David Contois; Bruce E Johnson; C David Pendleton; Burkhardt Seifert; Charley Carter; Elizabeth J Read; Jay Greenblatt; Lois E Top; Morris I Kelsey; John D Minna; Jay A Berzofsky
Journal: J Clin Oncol Date: 2005-06-27 Impact factor: 44.544

Review 5. Inflammatory networks and immune surveillance of pancreatic carcinoma.

Authors: Robert H Vonderheide; Lauren J Bayne
Journal: Curr Opin Immunol Date: 2013-02-17 Impact factor: 7.486

6. An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme.

Authors: John H Sampson; Gary E Archer; Duane A Mitchell; Amy B Heimberger; James E Herndon; Denise Lally-Goss; Sharon McGehee-Norman; Alison Paolino; David A Reardon; Allan H Friedman; Henry S Friedman; Darell D Bigner
Journal: Mol Cancer Ther Date: 2009-10 Impact factor: 6.261

7. Epitope landscape in breast and colorectal cancer.

Authors: Neil H Segal; D Williams Parsons; Karl S Peggs; Victor Velculescu; Ken W Kinzler; Bert Vogelstein; James P Allison
Journal: Cancer Res Date: 2008-02-01 Impact factor: 12.701

8. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research.

Authors: Martin A Cheever; James P Allison; Andrea S Ferris; Olivera J Finn; Benjamin M Hastings; Toby T Hecht; Ira Mellman; Sheila A Prindiville; Jaye L Viner; Louis M Weiner; Lynn M Matrisian
Journal: Clin Cancer Res Date: 2009-09-01 Impact factor: 12.531

Review 9. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.

Authors: Robert D Schreiber; Lloyd J Old; Mark J Smyth
Journal: Science Date: 2011-03-25 Impact factor: 47.728

10. Targeting the tumor mutanome for personalized vaccination therapy.

Authors: Sebastian Kreiter; John C Castle; Ozlem Türeci; Ugur Sahin
Journal: Oncoimmunology Date: 2012-08-01 Impact factor: 8.110

19 in total

1. Melanoma vaccines: clinical status and immune endpoints.

Authors: Deena M Maurer; Lisa H Butterfield; Lazar Vujanovic
Journal: Melanoma Res Date: 2019-04 Impact factor: 3.599

2. The regulatory landscape for actively personalized cancer immunotherapies.

Authors: Cedrik M Britten; Harpreet Singh-Jasuja; Bruno Flamion; Axel Hoos; Christoph Huber; Karl-Josef Kallen; Samir N Khleif; Sebastian Kreiter; Michaela Nielsen; Hans-Georg Rammensee; Ugur Sahin; Thomas Hinz; Ulrich Kalinke
Journal: Nat Biotechnol Date: 2013-10 Impact factor: 54.908

Immunotherapy at large: the road to personalized cancer vaccines.

Review 1. Therapeutic cancer vaccines: current status and moving forward.

Review 2. From cancer genomics to cancer immunotherapy: toward second-generation tumor antigens.

Review 3. Cancer immunotherapy comes of age.

4. Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome.

Review 5. Inflammatory networks and immune surveillance of pancreatic carcinoma.

6. An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme.

7. Epitope landscape in breast and colorectal cancer.

8. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research.

Review 9. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.

10. Targeting the tumor mutanome for personalized vaccination therapy.

1. Melanoma vaccines: clinical status and immune endpoints.

2. The regulatory landscape for actively personalized cancer immunotherapies.

Review 3. The next steps in next-gen sequencing of cancer genomes.

Review 4. Drugging the undruggable RAS: Mission possible?

Review 5. Biomimetic and synthetic interfaces to tune immune responses.

Review 6. Lost in translation: animal models and clinical trials in cancer treatment.

Review 7. Heterogeneous responses in hepatocellular carcinoma: the achilles heel of immune checkpoint inhibitors.

Review 8. Integrating RNA sequencing into neuro-oncology practice.

9. Immunotherapy for Breast Cancer: What Are We Missing?

Review 10. Methods for improving the immunogenicity and efficacy of cancer vaccines.